These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 23235952)

  • 1. Clearance of middle molecules during haemodialysis and haemodiafiltration: new insights.
    Leypoldt JK; Holmes CJ; Rutherford P
    Nephrol Dial Transplant; 2012 Dec; 27(12):4245-7. PubMed ID: 23235952
    [No Abstract]   [Full Text] [Related]  

  • 2. Paradoxical clearance of hyaluronan fragments during haemodialysis and haemodiafiltration.
    Goswami N; Roessler A; Haditsch B; Hinghofer-Szalkay H; Schneditz D
    Nephrol Dial Transplant; 2012 Dec; 27(12):4420-2. PubMed ID: 22734111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dialysis modality on phosphate control : haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit.
    Davenport A; Gardner C; Delaney M;
    Nephrol Dial Transplant; 2010 Mar; 25(3):897-901. PubMed ID: 19875379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis.
    Schiffl H
    Eur J Med Res; 2007 Jan; 12(1):26-33. PubMed ID: 17363355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental haemodialysis.
    Wong J; Vilar E; Davenport A; Farrington K
    Nephrol Dial Transplant; 2015 Oct; 30(10):1639-48. PubMed ID: 26038351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients.
    Jørgensen MB; Idorn T; Knop FK; Holst JJ; Hornum M; Feldt-Rasmussen B
    Nephrol Dial Transplant; 2015 Mar; 30(3):513-20. PubMed ID: 25319937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodiafiltration versus high-flux haemodialysis: Effects on phosphate control and erythropoietin response.
    Oates T; Pinney JH; Davenport A
    Am J Nephrol; 2011; 33(1):70-5. PubMed ID: 21178336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose kinetics and dosage of mecillinam in renal failure and haemodialysis.
    Schapira A
    Clin Pharmacokinet; 1984; 9(4):364-70. PubMed ID: 6088153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration.
    Krieter DH; Hackl A; Rodriguez A; Chenine L; Moragues HL; Lemke HD; Wanner C; Canaud B
    Nephrol Dial Transplant; 2010 Jan; 25(1):212-8. PubMed ID: 19755476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Kt calculation as a quality indicator of haemodialysis adequacy].
    Molina Núñez M; Roca Meroño S; de Alarcón Jiménez RM; García Hernández MA; Jimeno Griño C; Alvarez Fernández GM; Navarro Parreño MJ; Pérez Silva FM
    Nefrologia; 2010; 30(3):331-6. PubMed ID: 20514099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease.
    Thompson-Culkin K; Zussman B; Miller AK; Freed MI
    J Int Med Res; 2002; 30(4):391-9. PubMed ID: 12235921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease.
    Webster A; Nistor I
    Nephrology (Carlton); 2016 Jun; 21(6):526-7. PubMed ID: 26921882
    [No Abstract]   [Full Text] [Related]  

  • 14. [Kinetics of metipranolol in patients with chronic kidney failure and during hemodialysis].
    Motán J; Mayer O; Spanĕl M
    Vnitr Lek; 1991 Mar; 37(3):285-92. PubMed ID: 1674391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
    Eriksson T; Höglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA
    J Pharm Pharmacol; 2003 Dec; 55(12):1701-6. PubMed ID: 14738599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid metabolism and its clinical significance in patients treated by continuous ambulatory peritoneal dialysis.
    Lipkin GW; Forbes MA; Cooper EH; Turney JH
    Nephrol Dial Transplant; 1993; 8(4):357-60. PubMed ID: 8390012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with haemodiafiltration stabilises vascular stiffness (measured by aortic pulse wave velocity) compared to haemodialysis.
    Charitaki E; Belman D; Davenport A
    Nephron Clin Pract; 2014; 128(1-2):185-91. PubMed ID: 25376668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Folates and vitamin B12 in chronic renal failure. A prospective study in haemodialysis patients (author's transl)].
    Hernández Nieto L; Brito Barroso ML; García Pérez J; Maceira Cruz B; Gonález García C
    Sangre (Barc); 1980; 25(5B):665-75. PubMed ID: 7466550
    [No Abstract]   [Full Text] [Related]  

  • 19. [Renal excretion of amino acids in patients on a regular dialysis program].
    Nádvorníková H; Schück O; Teplan V; Kaslíková J; Tomková D; Reitschlägerová V
    Vnitr Lek; 1994 Apr; 40(4):211-4. PubMed ID: 8184580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.